Stifel Financial’s Titan Pharmaceuticals TTNP Stock Holding History

Stifel Financial’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-5	Closed	-$62K	–	2619
2017 Q1	$62K	Sell	5 -4	-44%	-$56.3K	﹤0.01%	2460
2016 Q4	$133K	Hold	9	–	–	﹤0.01%	2333
2016 Q3	$195K	Hold	9	–	–	﹤0.01%	2193
2016 Q2	$182K	Buy	+9	New	+$192K	﹤0.01%	2282
2016 Q1	–	Sell	-9	Closed	-$147K	–	2382
2015 Q4	$147K	Buy	+9	New	+$147K	﹤0.01%	2179

Other funds holding TTNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MERSOM

Municipal Employees' Retirement System of Michigan Lansing, Michigan $8.81B AUM 10.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

WPA

Winning Points Advisors Boca Raton, Florida $74.8M AUM

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

Stifel Financial's TTNP Position: Q2 2017 in Review

Stifel Financial sold out of Titan Pharmaceuticals (TTNP) in Q2 2017, closing a stake of 5 shares — an estimated $62K sold.

Stifel Financial first reported a position in TTNP in Q4 2015 and held it in 5 quarters. The position peaked at $195K in Q3 2016. 35 funds tracked by Wall St. Rank hold TTNP as of Q2 2017.

Stifel Financial reported no remaining Titan Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Stifel Financial sold 5 Titan Pharmaceuticals shares in Q2 2017, an estimated $62K.
Stifel Financial first reported a position in Titan Pharmaceuticals in Q4 2015 and held it in 5 quarters.
Stifel Financial's Titan Pharmaceuticals position peaked at $195K in Q3 2016.
35 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2017.

Based on Stifel Financial's 13F filing for Q2 2017, filed 14 Aug 2017.